Breaking: UBS Reconfirms $70.0 Target Price On Mallinckrodt (NYSE:MNK) Shares, Reconfirms Their Original “Buy” Rating

December 7, 2017 - By Migdalia James

 Breaking: UBS Reconfirms $70.0 Target Price On Mallinckrodt (NYSE:MNK) Shares, Reconfirms Their Original

Investors sentiment decreased to 0.72 in Q2 2017. Its down 0.30, from 1.02 in 2017Q1. It dropped, as 49 investors sold Mallinckrodt Public Limited Company shares while 136 reduced holdings. 37 funds opened positions while 96 raised stakes. 95.02 million shares or 0.42% more from 94.62 million shares in 2017Q1 were reported.

158,690 were reported by Jacobs Levy Equity Mgmt Incorporated. Nomura Asset Mngmt Co holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 12,313 shares. State Treasurer State Of Michigan has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 32,612 shares. Bluemountain Capital Lc has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK). First Quadrant L P Ca accumulated 224,181 shares or 0.2% of the stock. Washington Comml Bank holds 0% or 3 shares. Parkside Comml Bank Tru owns 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 26 shares. Moreover, Meiji Yasuda Life Insurance has 0.06% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 8,290 shares. Prudential, New Jersey-based fund reported 642,187 shares. Oregon Pub Employees Retirement Fund stated it has 47,777 shares. Winslow Evans And Crocker holds 80 shares. Serv Automobile Association accumulated 38,808 shares. 44,423 are held by Norinchukin Retail Bank The. Daiwa Secs Group Inc has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Proshare Advsrs Ltd Company holds 0.01% or 33,121 shares in its portfolio.

Mallinckrodt (NYSE:MNK) Rating Reaffirmed

Expert analysts at UBS now has a $70.0 target price on Mallinckrodt (NYSE:MNK). UBS and their recent target price gives a potential upside of 229.41 % from the company’s previous close. The rating has been revealed to clients and investors in analysts note on 6 October.

Investors sentiment decreased to 0.72 in Q2 2017. Its down 0.30, from 1.02 in 2017Q1. It dropped, as 49 investors sold Mallinckrodt Public Limited Company shares while 136 reduced holdings. 37 funds opened positions while 96 raised stakes. 95.02 million shares or 0.42% more from 94.62 million shares in 2017Q1 were reported.

158,690 were reported by Jacobs Levy Equity Mgmt Incorporated. Nomura Asset Mngmt Co holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 12,313 shares. State Treasurer State Of Michigan has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 32,612 shares. Bluemountain Capital Lc has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK). First Quadrant L P Ca accumulated 224,181 shares or 0.2% of the stock. Washington Comml Bank holds 0% or 3 shares. Parkside Comml Bank Tru owns 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 26 shares. Moreover, Meiji Yasuda Life Insurance has 0.06% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 8,290 shares. Prudential, New Jersey-based fund reported 642,187 shares. Oregon Pub Employees Retirement Fund stated it has 47,777 shares. Winslow Evans And Crocker holds 80 shares. Serv Automobile Association accumulated 38,808 shares. 44,423 are held by Norinchukin Retail Bank The. Daiwa Secs Group Inc has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Proshare Advsrs Ltd Company holds 0.01% or 33,121 shares in its portfolio.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 21 analysts covering Mallinckrodt (NYSE:MNK), 9 have Buy rating, 0 Sell and 12 Hold. Therefore 43% are positive. Mallinckrodt has $218 highest and $24.0 lowest target. $69.42’s average target is 226.68% above currents $21.25 stock price. Mallinckrodt had 86 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating by BMO Capital Markets given on Thursday, October 5. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Jefferies on Thursday, October 5. Barclays Capital downgraded Mallinckrodt Public Limited Company (NYSE:MNK) on Wednesday, November 8 to “Equal-Weight” rating. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Stifel Nicolaus on Friday, August 4. The company was maintained on Thursday, June 29 by UBS. On Wednesday, November 8 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm has “Neutral” rating by JP Morgan given on Wednesday, May 4. The firm earned “Buy” rating on Monday, August 7 by Mizuho. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Buy” rating given on Friday, February 3 by Mizuho. As per Tuesday, November 21, the company rating was downgraded by Oppenheimer.

The stock decreased 0.47% or $0.1 during the last trading session, reaching $21.25. About 2.24M shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 30.39% since December 7, 2016 and is downtrending. It has underperformed by 47.09% the S&P500.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.02 billion. The companyÂ’s Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It currently has negative earnings. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

More notable recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by: Prnewswire.com which released: “Mallinckrodt plc Presents Health Economic Data on Management of Infantile …” on December 04, 2017, also Seekingalpha.com with their article: “Express Scripts Sells Unit With Ties To Mallinckrodt’s Acthar” published on November 29, 2017, Streetinsider.com published: “Mallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray” on November 08, 2017. More interesting news about Mallinckrodt Public Limited Company (NYSE:MNK) were released by: Seekingalpha.com and their article: “Mallinckrodt: Where Does It Go From Here?” published on November 09, 2017 as well as Seekingalpha.com‘s news article titled: “Why Mallinckrodt Cratered” with publication date: November 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.